ID   NCI-H28
AC   CVCL_1555
SY   H28; H-28; NCIH28; HUT-28; HUT 28; HuT 28; HUT28; Hut28; HuT28
DR   CLO; CLO_0008079
DR   EFO; EFO_0006686
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-5820
DR   BioSample; SAMN03471010
DR   BioSample; SAMN10987612
DR   BioSamples; SAMEA100874
DR   CCLE; NCIH28_PLEURA
DR   Cell_Model_Passport; SIDM00720
DR   ChEMBL-Cells; CHEMBL3308775
DR   ChEMBL-Targets; CHEMBL1075541
DR   Cosmic; 688059
DR   Cosmic; 733814
DR   Cosmic; 877108
DR   Cosmic; 877350
DR   Cosmic; 886387
DR   Cosmic; 908470
DR   Cosmic; 980995
DR   Cosmic; 1032386
DR   Cosmic; 1146909
DR   Cosmic; 1152495
DR   Cosmic; 1481543
DR   Cosmic; 1522766
DR   Cosmic; 1541208
DR   Cosmic; 1749556
DR   Cosmic; 1963325
DR   Cosmic; 1995572
DR   Cosmic; 2474149
DR   Cosmic; 2758840
DR   Cosmic; 2758998
DR   Cosmic; 2759230
DR   Cosmic-CLP; 908470
DR   DepMap; ACH-000648
DR   GDSC; 908470
DR   GEO; GSM434272
DR   GEO; GSM726267
DR   GEO; GSM794268
DR   GEO; GSM850284
DR   GEO; GSM887425
DR   GEO; GSM888504
DR   GEO; GSM1670236
DR   IARC_TP53; 21567
DR   IARC_TP53; 23623
DR   IGRhCellID; H28GEO
DR   KCLB; 90028
DR   LiGeA; CCLE_571
DR   PharmacoDB; NCIH28_1099_2019
DR   Progenetix; CVCL_1555
DR   Wikidata; Q54908002
RX   PubMed=1568228;
RX   PubMed=8806092;
RX   PubMed=11030152;
RX   PubMed=16630136;
RX   PubMed=17270034;
RX   PubMed=20164919;
RX   PubMed=21245096;
RX   PubMed=21642991;
RX   PubMed=22460905;
RX   PubMed=23830731;
RX   PubMed=24926545;
RX   PubMed=25485619;
RX   PubMed=25902174;
RX   PubMed=26011428;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28553954;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31803961;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136).
CC   Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Arg146Alafs*48 (c.438-24_438-2del23); Zygosity=Homozygous (PubMed=21642991; PubMed=26011428).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=65.11%; Native American=0.21%; East Asian, North=3.2%; East Asian, South=0%; South Asian=0%; European, North=16.44%; European, South=15.05% (PubMed=30894373).
CC   Discontinued: KCLB; 90028; probable.
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 11,13
ST   D16S539: 12,13
ST   D18S51: 19
ST   D21S11: 29,30
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 10,12
ST   D8S1179: 10,12
ST   FGA: 19.2,21
ST   Penta D: 9,10
ST   Penta E: 10,16
ST   TH01: 7,9
ST   TPOX: 11
ST   vWA: 14,15
DI   NCIt; C45663; Pleural sarcomatoid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-09-21; Version: 32
//
RX   PubMed=1568228;
RA   Metcalf R.A., Welsh J.A., Bennett W.P., Seddon M.B., Lehman T.A.,
RA   Pelin K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B.I.,
RA   Harris C.C.;
RT   "p53 and Kirsten-ras mutations in human mesothelioma cell lines.";
RL   Cancer Res. 52:2610-2615(1992).
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=16630136; DOI=10.1111/j.1349-7006.2006.00184.x;
RA   Usami N., Fukui T., Kondo M., Taniguchi T., Yokoyama T., Mori S.,
RA   Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.;
RT   "Establishment and characterization of four malignant pleural
RT   mesothelioma cell lines from Japanese patients.";
RL   Cancer Sci. 97:387-394(2006).
//
RX   PubMed=17270034; DOI=10.1111/j.1349-7006.2006.00386.x;
RA   Taniguchi T., Karnan S., Fukui T., Yokoyama T., Tagawa H., Yokoi K.,
RA   Ueda Y., Mitsudomi T., Horio Y., Hida T., Yatabe Y., Seto M.,
RA   Sekido Y.;
RT   "Genomic profiling of malignant pleural mesothelioma with array-based
RT   comparative genomic hybridization shows frequent non-random
RT   chromosomal alteration regions including JUN amplification on 1p32.";
RL   Cancer Sci. 98:438-446(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21245096; DOI=10.1158/0008-5472.CAN-10-2164;
RA   Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T.,
RA   Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H.,
RA   Sekido Y.;
RT   "LATS2 is a tumor suppressor gene of malignant mesothelioma.";
RL   Cancer Res. 71:873-883(2011).
//
RX   PubMed=21642991; DOI=10.1038/ng.855;
RA   Bott M.J., Brevet M., Taylor B.S., Shimizu S., Ito T., Wang L.,
RA   Creaney J., Lake R.A., Zakowski M.F., Reva B., Sander C., Delsite R.,
RA   Powell S., Zhou Q., Shen R., Olshen A.B., Rusch V., Ladanyi M.;
RT   "The nuclear deubiquitinase BAP1 is commonly inactivated by somatic
RT   mutations and 3p21.1 losses in malignant pleural mesothelioma.";
RL   Nat. Genet. 43:668-672(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23830731; DOI=10.1016/j.cancergen.2013.04.006;
RA   Klorin G., Rozenblum E., Glebov O.K., Walker R.L., Park Y.,
RA   Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.;
RT   "Integrated high-resolution array CGH and SKY analysis of homozygous
RT   deletions and other genomic alterations present in malignant
RT   mesothelioma cell lines.";
RL   Cancer Genet. 206:191-205(2013).
//
RX   PubMed=24926545; DOI=10.1097/JTO.0000000000000202;
RA   Riquelme E., Suraokar M.B., Rodriguez J., Mino B., Lin H.Y.,
RA   Rice D.C., Tsao A., Wistuba I.I.;
RT   "Frequent coamplification and cooperation between C-MYC and PVT1
RT   oncogenes promote malignant pleural mesothelioma.";
RL   J. Thorac. Oncol. 9:998-1007(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25902174; DOI=10.1097/JTO.0000000000000493;
RA   Miyanaga A., Masuda M., Tsuta K., Kawasaki K., Nakamura Y., Sakuma T.,
RA   Asamura H., Gemma A., Yamada T.;
RT   "Hippo pathway gene mutations in malignant mesothelioma: revealed by
RT   RNA and targeted exon sequencing.";
RL   J. Thorac. Oncol. 10:844-851(2015).
//
RX   PubMed=26011428; DOI=10.1111/cas.12698;
RA   Hakiri S., Osada H., Ishiguro F., Murakami H., Murakami-Tonami Y.,
RA   Yokoi K., Sekido Y.;
RT   "Functional differences between wild-type and mutant-type
RT   BRCA1-associated protein 1 tumor suppressor against malignant
RT   mesothelioma cells.";
RL   Cancer Sci. 106:990-999(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28553954; DOI=10.1038/onc.2017.147;
RA   Kato T., Sato T., Yokoi K., Sekido Y.;
RT   "E-cadherin expression is correlated with focal adhesion kinase
RT   inhibitor resistance in merlin-negative malignant mesothelioma
RT   cells.";
RL   Oncogene 36:5522-5531(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31803961; DOI=10.1002/jcb.29564;
RA   Mulshine J.L., Ujhazy P., Antman M., Burgess C.M., Kuzmin I.,
RA   Bunn P.A. Jr., Johnson B.E., Roth J.A., Pass H.I., Ross S.M.,
RA   Aldige C.R., Wistuba I.I., Minna J.D.;
RT   "From clinical specimens to human cancer preclinical models -- a journey
RT   the NCI-cell line database-25 years later.";
RL   J. Cell. Biochem. 121:3986-3999(2020).
//